- Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, to participate in the premier cell and gene therapy industry conference, October 5–7, 2026, in Phoenix, Arizona
DALLAS, Sept. 29, 2026 — Terapéutica del nanoscopio, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, will deliver an Innovation Spotlight presentation at the Cell & Gene Meeting on the Mesa 2026, taking place October 5–7, 2026 in Phoenix, Arizona. The meeting is organized by the Alliance for Regenerative Medicine (ARM), which unites the cell and gene therapy ecosystem to modernize healthcare systems, overcome obstacles to innovation, and improve patient access to life-changing treatments.
Detalles de la presentación:
Cell & Gene Meeting on the Mesa 2026
Sesión: Innovation Spotlights
Presentador: Samarendra Mohanty, President
Fecha y hora: Tuesday, October 6, 2026, 11:15 AM
Ubicación: The Arizona Biltmore Hotel, Phoenix, Arizona
During his presentation, Dr. Mohanty will provide a company update on Nanoscope’s progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company’s Biologics License Application (BLA), currently under FDA review. Members of the Nanoscope leadership will be available to meet. Investors and potential partners should schedule a meeting via the partnering App or reach out to Nanoscope directly.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
La tecnología de opsina multicaracterística (MCO) de Nanoscope utiliza una opsina sintética patentada, modificada genéticamente, para optimizar su rendimiento en términos de alta sensibilidad a la luz en un amplio espectro y una cinética rápida. Tras la concepción e invención de la tecnología por parte de Samarendra Mohanty, cofundador, presidente y director científico de Nanoscope, su equipo ha dedicado más de una década a evaluar su rendimiento en diversos modelos animales y enfermedades humanas. MOGENRY es una terapia génica optogenética intravítrea experimental, de una sola aplicación y administrada en consulta, basada en la plataforma MCO de Nanoscope. Al administrar un gen de opsina multicaracterística a las células bipolares de la retina, de alta densidad, MOGENRY confiere a estas células supervivientes sensibilidad directa a la luz, permitiéndoles utilizar el circuito visual restante tras la pérdida de fotorreceptores. MOGENRY no requiere pruebas genéticas, cirugía invasiva ni dosis repetidas, y está diseñado para su administración dentro de los flujos de trabajo habituales en las consultas de retina.
Acerca de Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY. If approved, MOGENRY has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).
Contacto:
Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.com
FUENTE Terapéutica del Nanoscopio